Scarica l'app Stockscreener
11.41
5.06%
0.55
Pre-mercato:
11.41
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché KROS Giù?
Forum
Previsione
Precedente Chiudi:
$10.86
Aprire:
$11.46
Volume 24 ore:
2.85M
Relative Volume:
2.30
Capitalizzazione di mercato:
$462.19M
Reddito:
-
Utile/perdita netta:
$-168.05M
Rapporto P/E:
-2.2242
EPS:
-5.13
Flusso di cassa netto:
$-146.15M
1 W Prestazione:
-8.57%
1M Prestazione:
-33.00%
6M Prestazione:
-76.42%
1 anno Prestazione:
-78.45%
Intervallo 1D:
$11.06
$11.60
Intervallo di 1 settimana:
$9.775
$11.63
Portata 52W:
$9.775
$73.00
Keros Therapeutics Inc Stock (KROS) Company Profile
Nome
Keros Therapeutics Inc
Settore
Industria
Telefono
617-314-6297
Indirizzo
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
Confronta KROS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KROS
Keros Therapeutics Inc
|
11.41 | 462.19M | 0 | -168.05M | -146.15M | -5.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-17 | Downgrade | Wedbush | Outperform → Neutral |
| 2024-12-16 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-12-16 | Reiterato | Oppenheimer | Outperform |
| 2024-12-13 | Reiterato | H.C. Wainwright | Buy |
| 2024-12-12 | Downgrade | BTIG Research | Buy → Neutral |
| 2024-12-12 | Downgrade | TD Cowen | Buy → Hold |
| 2024-12-12 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2024-11-05 | Iniziato | Jefferies | Buy |
| 2024-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-09-23 | Iniziato | Guggenheim | Buy |
| 2024-06-25 | Iniziato | Oppenheimer | Outperform |
| 2024-02-21 | Iniziato | William Blair | Outperform |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-07-31 | Iniziato | Wedbush | Outperform |
| 2023-07-26 | Iniziato | BofA Securities | Buy |
| 2023-02-14 | Iniziato | Cowen | Outperform |
| 2022-10-18 | Iniziato | Truist | Buy |
| 2022-07-26 | Iniziato | BTIG Research | Buy |
| 2020-12-08 | Reiterato | H.C. Wainwright | Buy |
| 2020-05-04 | Iniziato | H.C. Wainwright | Buy |
| 2020-05-04 | Iniziato | Jefferies | Buy |
| 2020-05-04 | Iniziato | Piper Sandler | Overweight |
| 2020-05-04 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Keros Therapeutics Inc Borsa (KROS) Ultime notizie
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Keros Therapeutics, Inc.KROS - PR Newswire
Keros spikes as Teva deal takes effect; Cantor downgrades on trial setback - MSN
Keros Therapeutics, Inc. (KROS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - Markets Insider
Keros stock spikes as Teva deal takes effect (KROS:NASDAQ) - Seeking Alpha
Keros stock climbs on Takeda deal effectiveness - MSN
Keros Therapeutics stock rating cut to Neutral, cites dosing setback - MSN
Keros Therapeutics (NASDAQ:KROS) Downgraded by Cantor Fitzgerald to Neutral - MarketBeat
Keros Therapeutics seals $200M deal with Takeda - Investing.com
Keros Therapeutics stock rating cut to Neutral, cites dosing setback By Investing.com - Investing.com Canada
Keros Therapeutics Announces Effectiveness of Global License Agreement with Takeda to Advance Elritercept - The Manila Times
Keros Therapeutics Secures $200M Upfront Payment in Major Takeda Licensing Deal for Elritercept - StockTitan
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Keros Therapeutics, Inc. (KROS) and Encourages Stockholders to Learn More About the Investigation - Markets Insider
Down -36.23% in 4 Weeks, Here's Why Keros Therapeutics (KROS) Looks Ripe for a Turnaround - Yahoo Finance
Keros Therapeutics’ (KROS) “Neutral” Rating Reiterated at Guggenheim - Defense World
The week in pharma: action, reaction and insight – week to January 17 - The Pharma Letter
Piper Sandler Lowers Keros Therapeutics (NASDAQ:KROS) Price Target to $15.00 - MarketBeat
Keros Therapeutics (NASDAQ:KROS) Downgraded to Neutral Rating by Wedbush - MarketBeat
Guggenheim Reiterates "Neutral" Rating for Keros Therapeutics (NASDAQ:KROS) - MarketBeat
Here's Why Keros Therapeutics (KROS) is Poised for a Turnaround After Losing -39.17% in 4 Weeks - MSN
Wedbush Downgrades Keros Therapeutics (KROS) - MSN
Scotiabank Lowers Keros Therapeutics (NASDAQ:KROS) Price Target to $41.00 - Defense World
Oppenheimer Has Lowered Expectations for Keros Therapeutics (NASDAQ:KROS) Stock Price - Defense World
Piper Sandler cuts Keros stock target to $15, keeps Overweight - MSN
Deep Dive Into Keros Therapeutics Stock: Analyst Perspectives (11 Ratings) - Benzinga
Oppenheimer Lowers Keros Therapeutics (NASDAQ:KROS) Price Target to $23.00 - MarketBeat
Keros Therapeutics price target lowered to $23 from $63 at Oppenheimer - MSN
Keros ends mid-stage trial for lead asset after adverse events - MSN
Keros stock price target cut on study termination - MSN
Keros Therapeutics Stock Heads For Record Low After Dosing Halt In Pulmonary Disease Trial, Retail Buzz Spikes - MSN
Scotiabank maintained Keros Therapeutics at Sector Outperform By Investing.com - Investing.com UK
Keros Therapeutics (NASDAQ:KROS) Sets New 52-Week LowWhat's Next? - MarketBeat
Keros Therapeutics drops another Phase II cibotercept trial - The Pharma Letter
Keros Therapeutics Shares Down After Halting Pulmonary Hypertension Treatment Trials - MarketWatch
Keros Therapeutics (NASDAQ:KROS) Shares Down 8.9%What's Next? - MarketBeat
Keros Therapeutics stock falls after trial halt By Investing.com - Investing.com Australia
Keros Therapeutics stock falls after trial halt - Investing.com
Keros stock slips as trial for lead asset ends (KROS:NASDAQ) - Seeking Alpha
Keros Therapeutics Halts Pulmonary Hypertension Treatment Trials Due to Adverse Effects - MarketWatch
Keros Therapeutics Announces Additional Update on the Phase 2 TROPOS Trial - The Manila Times
Analysts Set Keros Therapeutics, Inc. (NASDAQ:KROS) PT at $75.00 - Defense World
Keros Therapeutics (NASDAQ:KROS) Hits New 12-Month LowHere's Why - MarketBeat
Keros Therapeutics (NASDAQ:KROS) Trading Down 8.9%Here's What Happened - MarketBeat
Keros Therapeutics, Inc. (NASDAQ:KROS) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Keros Therapeutics Updates on Clinical Trials and Safety - TipRanks
Keros Therapeutics (NASDAQ:KROS) Reaches New 1-Year LowShould You Sell? - MarketBeat
Keros Therapeutics stock hits 52-week low at $15.31 - Investing.com India
Keros Therapeutics stock hits 52-week low at $15.31 By Investing.com - Investing.com UK
(KROS) Trading Report - Stock Traders Daily
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Keros Therapeutics, Inc.KROS - Longview News-Journal
Keros Therapeutics stock hits 52-week low at $15.67 By Investing.com - Investing.com Nigeria
Keros Therapeutics (NASDAQ:KROS) Hits New 52-Week LowWhat's Next? - MarketBeat
Keros Therapeutics Inc Azioni (KROS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.81%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):